Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EKR Therapeutics has acquired exclusive marketing and distribution rights to DepoDur, a morphine sulfate extended release liposome injection, from San Diego-based Pacira Pharmaceuticals, which will continue to manufacture the product.
Subscribe to our email newsletter
Pacira says DepoDur is the only extended-release opioid that is approved by the FDA for epidural use. A single injection of DepoDur into the lumbar epidural space may provide pain relief for up to 48 hours following major surgery without the restrictions and potential complications associated with an indwelling epidural catheter.
“DepoDur is patent protected, addresses an important medical need in our market space, and has growth prospects that can be fully exploited through the application of EKR’s expertise and strengths in the acute care market,” said Howard Weisman, EKR’s chairman & CEO.
DepoDur was clinically developed as a proprietary treatment by Pacira R&D and it received FDA approval in 2004 for long-acting post-surgical pain management.